Physician's Weekly
JUNE 18, 2025
Cost-sharing interventions and patient education can help improve access to GLP-1 receptor agonists for patients with obesity, according to an abstract presented at the AACE Annual Meeting 2025. Other Persistent Barriers & Potential Solutions In another article not presented at the meeting, Stephanie W.
FDA Law Blog
OCTOBER 3, 2022
Department of Health and Human Services (HHS) and the Department of Justice (DOJ) have aggressively pursued antikickback cases in the healthcare industry. See 42 U.S.C. 1320a-7b(b). Today, these two documents are key in navigating speaker programs in the industry.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GeriPal
JUNE 20, 2024
Incontinence and avoiding issues can present in an older individual, in some cases, just like they do a younger person. But then there is incontinence, which is the same term, same word, but actually presents as a geriatric syndrome. Most of the trials that have been conducted are conducted by the manufacturers of those medications.
GeriPal
MAY 8, 2025
Alex 00:59 And I met all three of you and watched you do a presentation about psilocybin research at the Congress International Desens Palliative Miguel. Alex 06:03 Is psilocybin that’s used for medicinal purposes in your studies, for example, is that manufactured or is it derived directly from mushrooms? So when we did have.
FDA Law Blog
AUGUST 21, 2023
It’s important to note here that the warnings and precautions listed in the acetaminophen labeling complied with FDA’s Pregnancy Rule (which applies to all OTC systemic products), stating “if pregnant or breast-feeding ask a health professional before use,” and with the acetaminophen OTC Monograph and the relevant NDAs.
GeriPal
MARCH 24, 2022
The challenge is not that people made decisions differently, and it was difficult, the challenge was the healthcare professionals who said, “This is not working for me. First of all, this does feel primarily like a manufactured controversy. It was to the people who were asking for the decision to be made. I need structure.”
FDA Law Blog
MAY 21, 2024
The Attorney General, after considering HHS’ recommendations, “concludes that there is, at present, substantial evidence that marijuana does not warrant control under schedule I.” The Attorney General also released DOJ’s Office of Legal Counsel (“OLC”) opinions providing the rationale and support for the NPRM. NPRM at 44,619.
Expert insights. Personalized for you.
52 
Let's personalize your content